Beigene rebrands as BeOne Medicines, Korea unit to adopt new name from June 30

Global oncology firm Beigene has announced a major rebranding, relaunching under the new name BeOne Medicines Ltd., and shifting its legal incorporation from the Cayman Islands to Switzerland.

As part of this transformation, the company's Korean subsidiary will also change its name to BeOne Medicines Korea effective June 30, signaling a broader move to unify its global operations under a single identity.

The name change, approved at the company’s annual shareholder meeting on April 28, underscores BeOne’s commitment to reinforcing its presence as a global biotech leader.

BeOne’s Chairman and CEO John V. Oyler described the rebrand as “more than a name change.”

“BeOne symbolizes our identity as a unified force -- patients, caregivers, scientists, medical professionals, and governments -- joined together to overcome cancer,” Oyler said. “The remarkable commercial growth of Brukinsa (ingredient: zanubrutinib), the expanding potential of our immunotherapy asset Tevimbra (tislelizumab), and our robust pipeline of over 50 oncology assets are propelling us into a new era.”

At the core of its portfolio is Brukinsa, a BTK inhibitor that holds the broadest set of indications among its class.

The drug currently leads in new patient market share across all approved indications in the U.S.

The company is also developing late-stage assets such as sonrotoclax, a BCL2 inhibitor, and BGB-16673, a BTK degrader developed through the company’s proprietary CDAC (Covalent Degrader Antibody Conjugate) platform.

BeOne is also aggressively expanding its portfolio into solid tumors, including breast, lung, and gastrointestinal cancers. The company is actively advancing technologies such as multispecific antibodies, protein degraders, and antibody-drug conjugates (ADCs) to drive the next wave of oncology innovation.